April 22, 2014 – The U.S. Food and Drug Administration has just approved Cyramza (ramucirumab) to treat patients with advanced stomach cancer or gastroesophageal junction adenocarcinoma, a form of cancer located in the region where the esophagus joins the stomach. …

FDA approves Ramucirumab [Cyramza] for stomach cancer Read more »